Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.3857 +0.0079 (+2.09%)
Streaming Delayed Price Updated: 10:24 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
21 22 Next >
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
Is Bluebird Bio Stock a Buy?
This biotech looks cheap, but is it a value trap? 
Via The Motley Fool
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
Where Will Bluebird Bio Be in 1 Year?
Things could get better for the biotech, but they could also get worse. 
Via The Motley Fool
1 Beaten-Down Stock That Could Soar by 89%, According to Wall Street
Are you feeling brave? 
Via The Motley Fool
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
From bluebird bio, Inc.
Via Business Wire
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches... 
Via Benzinga
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
These two biotechs have a lot in common, but one is much better capitalized. 
Via The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Good medicines aren't always good business. 
Via The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
These companies are innovators, something that can prove highly lucrative. 
Via The Motley Fool
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Find out why analysts have such high expectations for these stocks. 
Via The Motley Fool
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Is Bluebird Bio a Bargain Buy in September?
With multiple near-term growth catalysts in play, expectations are already high. 
Via The Motley Fool
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle. 
Via The Motley Fool
1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street
Is this stock a value buy or a value trap? 
Via The Motley Fool
7 Very Oversold Nasdaq Stocks to Buy Right Now
The worries that have pushed the Nasdaq down sharply are overdone. Here are seven oversold Nasdaq oversold Nasdaq investment opportunities. 
Via InvestorPlace
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
From bluebird bio, Inc.
Via Business Wire
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Tuesday. Here are some big stocks recording gains in today’s session. Paymentus Holdings, Inc. (NYSE: PAY) shares rose 29.4% to... 
Via Benzinga
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
2 Magnificent Growth Stocks I'm Buying Hand Over Fist Right Now
These two growth stocks could deliver stellar returns over the long term. 
Via The Motley Fool
3 Stocks to Buy for Lottery Jackpot Style Returns
Although you can try your hand at the lottery, your odds of success are probably far better with stocks with high returns. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.